# Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

> **NCT03771157** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Rochester** · enrollment: 33 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Waldenstrom Macroglobulinemia (WM)

## Interventions

- **DRUG:** Shingrix vaccine

## Key facts

- **NCT ID:** NCT03771157
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-08-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03771157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03771157, "Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT03771157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*